Peterson B A, Bloomfield C D, Gottlieb A J, Coleman M, Greenberg M S
Cancer Treat Rep. 1982 Mar;66(3):563-6.
Twenty-nine adults with advanced acute nonlymphocytic leukemia were treated with an intensive chemotherapy program consisting of 5-azacitidine and zorubicin. Overall, eight patients (28%) achieved a complete remission. Although only one of 19 patients with refractory leukemia responded, seven of ten patients who were treated immediately following relapse from a prior remission achieved another complete remission. The duration of remission ranged from 5 to 33 weeks (median, 14). Treatment resulted in severe toxic reactions including myelosuppression, renal tubular dysfunction, and elevations in liver enzymes. In addition, each of the 15 patients who died of treatment-associated complications had a severe infection. This combination of 5-azacitidine and zorubicin is relatively ineffective for truly refractory leukemia, but it may be a useful alternative following relapse.
29名成年晚期急性非淋巴细胞白血病患者接受了由5-阿扎胞苷和柔红霉素组成的强化化疗方案治疗。总体而言，8名患者（28%）实现了完全缓解。虽然19名难治性白血病患者中只有1名有反应，但10名先前缓解后复发后立即接受治疗的患者中有7名再次实现了完全缓解。缓解期为5至33周（中位数为14周）。治疗导致了严重的毒性反应，包括骨髓抑制、肾小管功能障碍和肝酶升高。此外，死于治疗相关并发症的15名患者均发生了严重感染。5-阿扎胞苷和柔红霉素的这种联合用药对真正难治性白血病相对无效，但在复发后可能是一种有用的替代方案。
